Premium
Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent
Author(s) -
Lee Heidi,
Ryan James,
Mullett George,
Lawlor Brian A.
Publication year - 1994
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470090410
Subject(s) - risperidone , neuroleptic malignant syndrome , atypical antipsychotic , antipsychotic , medicine , antipsychotic agent , adverse effect , pharmacology , schizophrenia (object oriented programming) , psychiatry
Neuroleptic malignant syndrome (NMS) is a rare and sometimes fatal adverse reaction to neuroleptic drugs. Atypical antipsychotic agents, such as risperidone, are thought to be less likely to cause NMS because of their pharmacological profile. This is a case report of NMS associated with risperidone treatment.